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Transcription factorGap junctions are specialized cell–cell junctions that directly link the cytoplasm of neighboring cells. They
mediate the direct transfer of metabolites and ions from one cell to another. Discoveries of human genetic
disorders due to mutations in gap junction protein (connexin [Cx]) genes and experimental data on connexin
knockout mice provide direct evidence that gap junctional intercellular communication is essential for tissue
functions and organ development, and that its dysfunction causes diseases. Connexin-related signaling also
involves extracellular signaling (hemichannels) and non-channel intracellular signaling. Thus far, 21
human genes and 20 mouse genes for connexins have been identiﬁed. Each connexin shows tissue- or cell-
type-speciﬁc expression, and most organs and many cell types express more than one connexin. Connexin
expression can be regulated at many of the steps in the pathway from DNA to RNA to protein. In recent
years, it has become clear that epigenetic processes are also essentially involved in connexin gene expression.
In this review, we summarize recent knowledge on regulation of connexin expression by transcription factors
and epigenetic mechanisms including histone modiﬁcations, DNA methylation, and microRNA. This article is
part of a Special Issue entitled: The communicating junctions, roles and dysfunctions.
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Gap junctions are specialized cell–cell junctions that directly link the
cytoplasm of neighboring cells. They mediate the direct transfer of
metabolites and ions from one cell to another. Therefore, it has long
been hypothesized that gap junctional intercellular communication
plays a crucial role in the maintenance of homeostasis, morphogenesis,
cell differentiation, and growth control in multicellular organisms.
Discoveries of human genetic disorders due to mutations in gap
junction protein (connexin [Cx]) genes and experimental data on
connexin knockout mice provide direct evidence that gap junctional
intercellular communication is essential for tissue functions and organ
development, and that its dysfunction causes diseases. Connexin-
related signaling also involves extracellular signaling (hemichannels)
and non-channel intracellular signaling.
Connexin proteins are named after their speciﬁc molecular weight
in kDa (for instance, Cx43 has a mobility of 43 kDa). Twenty-one
human genes and 20 mouse genes for connexins have been identiﬁed
[1]. Their genes have been classiﬁed into 5 groups (alpha, beta,
gamma, delta, and epsilon) based on sequence homology and thus
the genes are named accordingly (for instance Cx43, which is the
ﬁrst connexin of the alpha-group, is coded by GJA1) (http://www.
genenames.org/genefamilies/GJ). Each connexin shows tissue- or
cell-type-speciﬁc expression, and most organs and many cell types
express more than one connexin (Table 1). Some connexins, such as
Cx32 and Cx43, are expressed in cells of many types, but others are
expressed in very limited organs and cells. Even in the same tissue,Table 1
Human gap junction protein (connexin) genes.
Approved symbol Approved name Synonyms
GJA1 Gap junction protein, alpha 1, 43 kDa Cx43
GJA3 Gap junction protein, alpha 3, 46 kDa Cx46
GJA4 gap junction protein, alpha 4, 37 kDa Cx37
GJA5 Gap junction protein, alpha 5, 40 kDa Cx40
GJA8 Gap junction protein, alpha 8, 50 kDa Cx50
GJA9 Gap junction protein, alpha 9, 59 kDa Cx59, Cx58
GJA10 Gap junction protein, alpha 10, 62 kDa Cx62, mouse Cx57
GJB1 Gap junction protein, beta 1, 32 kDa Cx32
GJB2 Gap junction protein, beta 2, 26 kDa Cx26
GJB3 Gap junction protein, beta 3, 31 kDa Cx31
GJB4 Gap junction protein, beta 4, 30.3 kDa Cx30.3
GJB5 Gap junction protein, beta 5, 31.1 kDa Cx31.1
GJB6 Gap junction protein, beta 6, 30 kDa Cx30
GJB7 Gap junction protein, beta 7, 25 kDa Cx25
GJC1 Gap junction protein, gamma 1, 45 kDa Cx45
GJC2 Gap junction protein, gamma 2, 47 kDa Cx47, Cx46.6,
GJC3 Gap junction protein, gamma 3, 30.2 kDa Cx30.2
GJD2 Gap junction protein, delta 2, 36 kDa Cx36
GJD3 Gap junction protein, delta 3, 31.9 kDa Cx31.9, Cx30.2
GJD4 Gap junction protein, delta 4, 40.1 kDa Cx40.1
GJE1 Gap junction protein, epsilon 1, 23 kDa Cx23the expression pattern of each connexin shows cell-type speciﬁcity
and developmental changes, suggesting the presence of distinct but
tight control mechanisms for regulation of connexin gene expression.
For example, in the adult mouse heart tissue [2,3], Cx43, encoded by
the Gja1 gene, is expressed in all the cardiac components excluding
the sinoatrial node (SAN) and atrioventricular node (AVN), the His
bundle, and the proximal parts of the bundle branches (BBs). On the
other hand, Cx40, encoded by Gja5, expression is restricted to the
atrial myocytes, the AV node, and the His–Purkinje system. Similarly,
Cx45, encoded by Gjc1, is restricted to the SAN and AVN, around the
His bundle, and the most peripheral regions of the interventricular
septum. Cx30.2, encoded by Gjd3, is expressed in the SAN and AVN,
and to a lesser extent in the His bundle and its branches. Cx30.2 con-
tributes to slow down impulse propagation in the AVN, and to limit
the number of beats conducted from atria to ventricles. Cx30,
encoded by Gjb6, is functionally expressed, in low abundance, in the
SAN.
Cell coupling via gap junctions is dependent on the speciﬁc pat-
tern of connexin gene expression [4]. This pattern of gene expression
is altered during development and in several pathological conditions
resulting in changes of cell coupling and probably connexin hemi-
channel function [5]. Like other genes, connexin expression can be
regulated at many of the steps in the pathway from DNA to RNA to
protein, i.e., transcriptional control, RNA processing control, RNA
transport and localization control, translational control, mRNA degra-
dation control, and protein activity control [6,7]. More recently the
contributions of epigenetic and post-transcriptional mechanismsChromosome Major expressed organ or cell types
6q22-q23 Many cell types
13q12.11 Lens
1p35.1 Endothelium, granulosa cells, lung, skin
1q21.1 Cardiac atrium and conduction system, endothelium
1q21.1 Lens
1p34 –
6q15-q16 Retinal horizontal cells
Xq13.1 Hepatocytes, secretory acinar cells, Schwann cells
13q11-q12 Cochlea, placenta, hepatocytes, skin, pancreas, kidney, intestine
1p34 Cochlea, placenta, skin
1p35-p34 Skin, kidney
1p34.3 Skin
13q12 Astrocytes, cochlea
6q15 –
17q21.31 SAN, AVN, smooth muscle cells, neurons
1q41-q42 Oligodendrocytes, spinal cord, lymphatics
7q22.1 Brain, spinal cord, Schwann cells
15q13.1 Neurons, pancreatic β-cells
17q21.1 SAN, AVN
10p11.22 –
6q24.1 –
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been identiﬁed in regulation of connexin expression [8]. In the previ-
ous review [9], we focused on the structure of connexin genes, and
transcriptional factors and biological substances that regulate con-
nexin expression. In the current review, we will add new information
on regulation of connexin expression by transcription factors and epi-
genetic mechanisms.
2. Gene structure of gap junction proteins (connexins)
Initial studies seemed to show that the general genomic structure of
connexin genes is rather simple, i.e., a 5′-untranslated region (5′-UTR)
on exon 1 is separated from the complete connexin coding region and
the subsequent 3′-untranslated region (3′-UTR), both located on exon
2. However, current data on genomic organization of various connexin
genes refutes this simplicity. First,many different splice isoforms of sev-
eral connexin genes have thus far been identiﬁed, indicating that differ-
ent 5′-UTRs can be spliced in a consecutive and/or alternate manner
possibly due to alternate promoter usage. However, it should be em-
phasized that these transcript isoforms vary only in their untranslated,
mostly 5′-UTRs that leave the coding region unaltered. Second, the cod-
ing region can be interrupted by introns, e.g., mouse Cx36 (Gjd2) [10],
Cx39 (Gjd4) [11], Cx57 (Gja10) genes [12], and human Cx59 (GJA9)
[13]. We will discuss the gene structure of several connexin genes in
some detail in the following sections.
2.1. Cx43 (GJA1)
Cx43 gene was originally described as consisting of two exons, one
containing most of the 5′-UTR and the other containing the protein
sequence and 3′-UTR [14–17]. However, Pfeifer et al. [18] reported
that in mice there are four additional exons, all of which code for
novel 5′-UTRs. They showed that altogether six exons, ﬁve of which
code for 5′-UTRs (exon 1A~1E), one for the coding region (exon 2),
and three alternate promoter regions (P1-P3) are present in the
mouse Cx43 gene, and that four of the six exons (exon 1A–1C,
exon2) found in the mouse are also present in the rat. No equivalents
of mouse exons 1D or 1Ewere found in the rat. In the human, however,
no alternate 5′-UTR has been found so far.
Pfeifer et al. [18] also showed that in the mouse, nine different
Cx43 mRNAs (transcripts E1As/E2, E1A/E2, E1AL/E2, E1A/E1E/E2,
E1Bs/E2, E1Bs/E1D/E2, E1BL/E2, E1C/E2, E1C/E1D/E2) are generated
by differential promoter usages and alternative splicing mechanisms.
In rats, six different Cx43 mRNA species (transcripts E1As/E2, E1A/E2,
E1AL/E2, E1B/E2, E1Cs/E2, E1CL/E2) were similarly found. In the
mouse Cx43 gene, in addition to the promoter P1, which was previ-
ously known to be a Cx43 promoter, two additional promoters down-
stream of promoter P1 were found; promoter P2 is located within
exon 1A, and promoter P3 is located in the intron just upstream of
exon 1C. In the heart, promoter P1 is active throughout the organ.
Promoter P2 is active in the atrium and septum but not in the ventri-
cle. Promoter P3 is functional only in ventricles and not in atria and
septum. Alternative splicing and exon choice seem to be cell-type
speciﬁc, because transcripts containing exon 1B preferentially skip
exon 1D in the septum, whereas in the atrium exon 1D is included
in about half of the transcripts.
Bierhuizen et al. [19] analyzed the expression of Cx43 RNA isoforms
in mouse calcineurin-induced cardiac hypertrophy. The expression
proﬁles for the different RNA Cx43 isoforms are very similar between
wild-type and calcineurin-induced hearts not only in the left ventricle
but also in the other parts of the heart.
Carystinos et al. [20] have proposed that the P2 promoter mediates
upregulation of Cx43 expression through the Ras signaling pathway
and the putative consensus sequence, AGTTC(A/C)A(T/C)CA, was
found in the human, mouse and rat Cx43 gene. They showed that thiselement is recognized by a protein complex that includes c-Myc and
HSP90.
2.2. Cx40 (GJA5)
Concerning Cx40 mRNA, two different transcripts are found in the
human [21], three different transcripts in the mouse [22], and one
transcript in the rat have been found. More importantly, these different
transcripts are transcribed in a tissue-speciﬁcmanner in the human and
mouse.
Dupays et al. [21] reported that human Cx40 gene contains at least
three exons, 1A, 1B and 2, which are present in two lineage-speciﬁc
variants: transcript 1A and transcript 1B are derived from alternative
5′ non-coding exons (exon 1A and 1B). Each of two exons is transcribed
independently [transcript 1A (E1A/E2) and transcript 1B (E1B/E2)].
These transcripts are transcribed in a cell-type-speciﬁc manner; e.g.,
human umbilical cord vein endothelial cells (HUVEC) express only
transcript 1A, while the human choriocarcinoma cell lines BeWo,
JAR, and JEG-3 and puriﬁed cytotrophoblasts from ﬁrst-trimester
human placenta express only transcript 1B. In the human heart, how-
ever, both transcripts were found to be expressed in various regions,
i.e., left atrium, right atrium, left ventricle, and right ventricle. Quan-
titative real-time RT-PCR analysis showed that transcript 1B is always
less abundant than transcript A in these different regions in the heart:
for example, transcript 1B was 3- and 28-fold less abundant than
transcript 1A in the left atrium and left ventricle.
In the mouse Cx40 gene, Anderson et al. [22] indentiﬁed three
5′-UTR exons, exon 1A, 1B, and AS, and three transcripts (E1A/E2,
E1B/E2, E1B/AS/E2). A transcript containing exon AS is nearly absent
in mouse embryo and heart, but it is especially abundant in the esoph-
agus. On the other hand, transcripts that include exon 1awere reported
to be ubiquitous in all the tissues tested. In addition, Bierhuizen et al.
[19] analyzed the expression of Cx40 RNA isoforms in mouse
calcineurin-induced cardiac hypertrophy. RNA consisting of E1A/E2
sequences could not be detected at all in wild type nor calcineurin-
induced atrial samples. The RNA isoforms consisting of E1B/E2 or
E1B/AS/E2 sequences are detectable in control RNA, but are largely
reduced in calcineurin-induced atrial RNA.
In the rat, no alternative Cx40 transcripts have so far been
reported [23]. Human Cx40 exon 1A is orthologous to the mouse
Cx40 exon 1B and rat Cx40 exon 1.
Tao and Valdimarsson [24] recently reported that zebraﬁsh Cx45.6
(the ortholog of mammalian Cx40) shows six isoforms of alternative
5′UTRs which are generated from multiple promoter usage and alter-
native pre-mRNA splicing. Cx45.6 undergoes tandem alternative
splicing, which produces transcripts only differing by 3 nucleotides.
Their work is the ﬁrst study that has demonstrated tandem alterna-
tive pre-mRNA splicing in the connexin gene family.
2.3. Cx32 (GJB1)
Miller et al. [25] ﬁrst reported the structure of the rat Cx32 gene
and showed that the 5′-UTR of the transcript in the liver contains a
6.1-kb intron and that transcription starts at non-coding exon (in
this review, the nomenclature used for an exon localized at most 5′
regions is exon 1) upstream of the intron, while the complete coding
sequence is not interrupted by an intron but contained within one
exon (in this review, the nomenclature used for this exon is exon
2). It is now known that multiple alternatively spliced transcripts of
Cx32 gene exist in mammalian species, i.e., two different transcripts
in the rat [26,27] and human [28], and three different transcripts in
the cow [29] and mouse [30]. It can be generalized that in the hepato-
cyte and secretory acinar cell, Cx32 mRNA is made from the promoter
1 (P1) upstream of exon 1 and in Schwann cells from an alternative
promoter 2 (P2) upstream of exon 1B that is located upstream of
the coding exon (exon 2). Therefore, promoter P2 is called nerve-
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downstream of the nerve-speciﬁc promoter of Cx32 gene is exon 1B).
In cattle and mice, exon 1A is localized between exon 1 and exon 1B.
The promoter P1 contains putative binding sites not only for cell
type-independent (ubiquitous) transcription factors, such as binding
sites for Sp1/Sp3 [31–33], nuclear factor 1 (NF-1) [34], and Yin Yang
1 (YY1) [33], but also for cell-type-dependent transcription factors in-
cluding hepatocyte nuclear factor-1 (HNF-1) [31,34,35]. The nerve-
speciﬁc promoter P2 also includes binding sites for cell-type-speciﬁc
transcription factors such as Sox10 and early growth response gene-
2 (Egr2/Knox20) [36,37]. Each transcription factor will be described
below.
2.4. Cx26 (GJB2)
In contrast to other connexin genes described above, thus far, only
two exons, i.e., non-coding exon 1 and exon 2 containing complete
connexin coding region and the subsequent 3′-UTR, are known to
be present in the mammalian Cx26 gene. In the mouse Cx26 gene,
the length is 234 bp for exon 1 and 3.8 kb for intron 1 [34]. Similarly,
in the human Cx26 gene, the length is 160 bp for exon 1 and 3148 bp
for intron 1 [38]. In the promoter P1 upstream of exon 1, several GC
boxes for Sp1/Sp3 binding sites and a TTAAAA box are identiﬁed in
the mouse [34] and human [38,39] Cx26 genes.
2.5. Cx31 (GJB3)
Three exons (exons 1A, 1B, and 2) have so far been identiﬁed in
the mouse Cx31 gene. The two exons that comprise the 5′-UTR,
exons 1A and 1B, lie ~3.7 kb and 2.3 kb upstream of exon 2 (coding
exon), respectively [22,40]. Anderson et al. [22] described exon 1A,
a novel exon, which appears to be transcribed from previously un-
known promoters. They showed that transcripts that include exon
1A are widely distributed in adult tissues, including the skin, but are
absent from the brain, and that multiple transcription start sites are
present in exon 1A.
Mouse exon 1B was cloned and described by Henneman et al. [41].
A proximal promoter region extending to 561 bp upstream of mouse
exon 1B serves as a basal promoter in both mouse embryonic stem
(ES) cells and a mouse keratinocyte-derived cell line. The rat exon 1
shows high homology (93%) with mouse exon 1B [40]. Two transcrip-
tion start sites are identiﬁed in exon 1 in the rat. However, in the
human Cx31 gene, only the second exon, which contains complete
coding region and a part of intron, has been characterized [42].
Both mouse Cx31 exon 1B and rat Cx31 exon 1 are preceded by
a TATA-less promoter region. No GC boxes (which may control
transcriptional initiation in TATA-less promoters) via binding to the
ubiquitous transcription factor Sp1 were found in the (basal) promoter
region [40,43]. In rat Cx31 promoter region (935 bp upstream of the 5′
ﬂanking region of exon 1), ﬁve putative GATA-2/GATA-3 binding sites,
and putative binding sites for NFκB, CCAAT-box, cEBPα/CEBβ, c-AMP
responsive element, and multiple E-box/E-box are found. Despite the
presence of multiple binding sites for GATA factors in the putative
promoter region of rat Cx31 gene, cotransfection experiments with
GATA-3 expression had no inﬂuence on the promoter activity of Cx31.
At further upstream of basal promoter region (between −3000 and
−2200 bp upstream), positive cell-speciﬁc regulatory element is
found in the rat Cx31 gene [40].
In the mouse, expression of Cx31 in keratinocytes and ES cells is
regulated by different cis-regulatory elements and differs in its re-
quirements for the intron in situ [43]. A region between 561 and
841 bp upstream of mouse Cx31 exon 1B is essential and sufﬁcient
for substantial transcription of Cx31 in mouse keratinocyte-derived
Hel37 cells, whereas an intron between exon 1B and exon 2 enhances
expression of Cx31 in ES cells but not in keratinocyte-derived cells.
Splicing is shown to be required for intron-dependent expressionenhancement of Cx31 in ES cells because mutations in the splice
donor site that prevent transcript processing cause decreased expres-
sion of Cx31. The enhancing effect of the intron of the rat Cx31 gene
was also found in the mouse keratinocyte line Hel37 as well as in
the choriocarcinoma cell line Rcho-1 [40].
2.6. Cx30 (GJB6)
Essenfelder et al. [44] reported that six different exons are present
in the human Cx30 gene. They showed that exon 1 to exon 5 are non-
coding exons while exon 6 is a coding exon, and that some of the
Cx30 exons can be alternatively spliced, so that the 5′ non-coding
region of Cx30 transcripts is highly variable. They found that in hair
follicle keratinocytes, at least four different splicing variants are pre-
sent and only exon 5 is present in all transcripts, whereas exon 3,
which has been described in human brain cDNA, is absent from Cx30
transcripts from epidermis. Their data suggest that in epidermis,
Cx30 transcription starts at exon 1, whereas in cells from the nervous
system transcription would start from exon 3.
In the promoter region of the human Cx30 gene, upstream of exon
1, a TATA motif (TTAAAA), several potential binding sites for Sp1, and
consensus sequence (CGCCCCCGC) for the early growth response
gene product (Egr)-binding are present [44].
2.7. Cx45 (GJC1)
Themouse Cx45 gene is composed of ﬁve exons (exons1A, 1B, 1C, 2,
and 3), two of which (exons 1A and 1B) were only very recently
reported [22]. Exons 1A, 1B, 1C, and 2 contain only 5′ untranslated
sequences, and exon 3 contains the remaining 5′-UTR, entire coding
sequence and 3′-UTR. Each of exon 1A, 1B, and 1C is spliced to exon
2 and exon 3. A transcript that directly starts at exon 2 is also present
[22,45]. Thus, various transcripts (E1A/E2/E3, E1B/E2/E3, E1C/E2/E3,
E2/E3) are generated. Transcription of Cx45 from each alternative pro-
moter is tissue-speciﬁc, i.e., although transcripts containing exon 1A is
nearly ubiquitous, exon 1B was found in trace amounts in colon RNA
and Exon 1C was found in colon, bladder, lung, skeletal muscle,
ovary, heart, and E14.5 embryo total RNA. Multiple upstream ORF are
found in exon 1A and exon 1C [22,45].
Teunissen et al. [46] performed comparative analysis of the Cx45
gene between human and mice, and revealed conservation of E2
and E3 sequence between the two species.
Baldridge et al. [47] found a potential TATA box and two putative
AP-1 binding sites in the 5′ region of the mouse Cx45 gene, but no
functional analysis of the regulatory region of Cx45 has yet been
performed.
The usage of alternative promoters to produce different 5′-UTR of
connexin mRNAs has also been reported on mouse Cx46 (Gja3) and
Cx47 (Gjc2) [22].
2.8. Cx36 (Gjd2), Cx39 (Gjd4), Cx57 (Gja10), and Cx59 (GJA9) genes,
whose coding regions are interrupted by introns
The coding regions of Cx36, Cx39, Cx57, and Cx59 genes have been
shown to be located on two (or more) different exons. The coding re-
gion is interrupted by a 1.14-kb intron, which separates the ﬁrst
71 bp, starting with ATG, from the rest of the coding region in the
rat [48,49] and mouse [49] Cx36 genes. The coding region of the
mouse Cx39 is also interrupted by a 1.5-kb intron, which separates
exon 1, coding 21 amino acids, and exon 2, coding 343 amino acids
[50]. Concerning mouse Cx57 gene, Hombach et al. [12] found that,
at least in the retina, these most C-terminal amino acid residues
were replaced after splicing with 12 different amino acid residues
coded further downstream. As a result, 97.6% (480 amino acids) of
the coding region of mouse Cx57 gene is located on exon 2, whereas
the residual 2.4% (12 amino acids) is encoded on a third exon, which
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coding regions that are interrupted by introns, these coding regions
have to be spliced properly in order to become translated. Otherwise
alternative splicing (which has not, however, been demonstrated yet)
would lead to a dramatic modiﬁcation of the connexin coding region.
3. Transcriptional factors, biological substances, and signal
transduction pathways that regulate expression of connexin genes
As described above, in most connexin genes, the basal (canonical,
proximal) promoter P1 is located within 300 bp upstream of the tran-
scription initiation site in exon 1. Within the region, binding sites for
cell type-independent (ubiquitous) and -dependent transcription fac-
tors have been identiﬁed in several connexin genes. For example, the
former include binding sites for TATA box-binding protein, Sp1/Sp3,
and AP-1. The latter include binding sites for cardiac-speciﬁc tran-
scription factors (Nkx2.5, Tbx5, Tbx2, Tbx3, GATA4 etc.) and HNF-1.
A sharp distinction between cell type-independent (ubiquitous) and
-dependent transcription factors is sometimes difﬁcult to make. How-
ever, we adopt this classiﬁcation for the convenience of description.
3.1. Cell type-independent (ubiquitous) transcription factors, biologi-
cal substances, and signal transduction pathways that regulate
connexin expression
3.1.1. Sp1
Sp1 is a ubiquitous transcription factor that has a DNA-binding
domain that consists of three zinc ﬁngers and recognizes the GC box.
Sp-1 binding sites have been identiﬁed in connexin genes, and they
appear to be a common important element in the basal transcriptional
activity of several connexin genes, such as Cx32 [31–33], Cx40
[21,51–54], Cx43 [55–61], and Cx26 [39,62]. For example, Teunissen et
al. [53,56] characterized the proximal promoters P1 of rat Cx40
(−175, +85) and Cx43 (−148, +281) genes, in which respectively
ﬁve and four potential binding sites for Sp-family transcription factors
were found. They showed that each of these sites contributes to pro-
moter activities and binds both the transcription factors Sp1 and Sp3.
They also demonstrated that both Sp1 and Sp3 activated the rat Cx40
and Cx43 promoters P1, and that random disruption of two of the
Sp1/Sp3 binding sites almost completely abolished promoter activity
of Cx40 genes.
Hernandez et al. [60] found that the Trichostatin A (TSA), an inhib-
itor of a histone deacetylase, induces Cx43 in human prostate cancer
cells. They provided evidence that the integrity of both Sp1 and a run
of AP-1 in a regulatory region between −234 and −287 from the
transcription start site of the basal Cx43 promoter is essential for
TSA-induced Cx43 promoter activity, showing that the Sp1/AP-1
responsive elements act in a synergy with the coactivator p300/
CREB-binding protein (CBP) in TSA-mediated Cx43 transcription.
This is accompanied by hyperacetylation of histones H4 surrounding
the AP-1- and Sp1-responsive gene elements.
Villares et al. [61] reported that up-regulation of protease-activated
receptor-1 (PAR-1) expression, seen in melanoma progression, medi-
ates high levels of Cx43 expression and that Cx43 promoter activity is
signiﬁcantly inhibited in PAR-1-silenced cells. Chromatin immunopre-
cipitation studies showed a reduction in the binding of SP-1 and AP-1
transcription factors to the promoter of Cx43 after PAR-1 silencing.
Makino et al. [63] showed that high-glucose treatment causes a
decrease in Cx40 protein expression in vascular endothelial cells
and impairs endothelial capillary network formation, and that the
hyperglycemia-induced decrease in Cx40 is associated with inhibited
protein expression of Sp1.
Concerning Cx32, Bai et al. [32] identiﬁed two Sp1 binding sites in
a basal promoter P1 localized between−179 bp and−134 bp in the
rat Cx32 gene. Piechocki et al. [31] also showed that speciﬁc nuclear
protein-DNA complexes that bound to Sp1 consensus sites withinthe rat Cx32 basal promoter element (nt −134 to −33) are formed
using nuclear extracts from both types of cells. The basal promoter el-
ement of rat Cx32 gene (nt −134 to −33) is 1.4-fold more active in
MH1C1 cells than in WB-F344 cells, whereas the entire promoter
fragment (nt −754 to −33) is four-fold more active in MH1C1
cells. Speciﬁc nuclear protein-DNA complexes that bound to Sp1 con-
sensus sites within the basal promoter P1 are formed using nuclear
extracts from both MH1C1 rat hepatoma cells that express endoge-
nous Cx32 and WB-F344 rat liver epithelial cells that do not. These
data indicate that Sp1 is necessary for Cx32 promoter P1 basal activ-
ity, but that some other transcription factor(s) determine the cell-
speciﬁc expression of Cx32.
3.1.2. Activator protein 1 (AP-1)
Activator protein 1 (AP-1) is composed of homo- or heterodimers
of the Jun, Fos, activating transcription factor (ATF), and musculoapo-
neurotic ﬁbrosarcoma (MAF) proteins via leucine zipper structure
and regulates various responses of cells to stimuli. AP-1 binds to a
consensus sequence [TGAC (T/G) TCA] in the promoter and induces
transcription of the gene. One or more AP-1-binding sites have been
identiﬁed in the mouse, rat, and human Cx43 proximal promoters
P1 (approximately 150 nucleotides up- and downstream of the tran-
scription initiation site) (the rat Cx43 promoter contains two AP-1-
binding sites [56], whereas the mouse and human promoters each
have one AP-1-binding site). The importance of AP-1 transcription
factors in regulation of Cx43 expression in the onset of labor by allow-
ing for an increase in myometrial muscle cell coupling has been dem-
onstrated [17,58,64].
Mitchell and Lye [65] reported that dimers comprising Fos/Jun
proteins conferred greater transcriptional activity than Jun dimers,
with the Fra-2/JunB combination conferring the greatest activity,
and that expression of Fra-2 increases earlier than other Fos family
members and confers the highest transcriptional drive to the Cx43
promoter, suggesting that Fra-2 is a central component in the regula-
tion of Cx43 expression during labor.
Tacheau et al. [66] found that TGF-beta1 induces Cx43 gene ex-
pression in normal murine mammary gland epithelial cells and that
c-Jun/AP-1 pathway together with p38 and PI3K/AKT pathways is in-
volved in mediating TGF-beta1-induced Cx43 gene expression.
Zi et al. [67] very recently reported that mitogen-activated protein
kinase kinase 4 (MKK4) deﬁciency in cardiomyocytes causes Cx43 re-
duction and couples hypertrophic signals to ventricular arrhythmo-
genesis. They found that two AP-1 binding sites, (−47, -39 from the
transcription start site) and (−122, -112 from the transcription
start site), in the Cx43 promoter region are responsible for the
MKK4-regulated Cx43 expression.
Negoro et al. [68] found that basic ﬁbroblast growth factor (bFGF)
up-regulates Cx43 transcription in urinary bladder smooth muscle
cells via the extracellular signal regulated kinase (ERK) 1/2-AP-1
pathway. They showed that Cx43 promoter activity is signiﬁcantly
up-regulated upon stimulation of bFGF and that the effect of bFGF
on Cx43 promoter is abolished by mutation or deletion of an AP-1
binding site (−49, −43) of the Cx43 promoter.
3.1.3. Cyclic AMP
It has long been known that cyclic AMP (cAMP) enhances gap
junction formation and gap-junctional intercellular communication
in many cell types. Concerning gap junctions made by Cx43, it is
now understood that such enhancement by cAMP is achieved via at
least two different mechanisms: initial rapid redistribution of Cx43
to the cell membrane, and later stimulation of Cx43 gene expression.
Putative camp (C/EBP)-responsive element had been identiﬁed in the
rat Cx43 proximal promoter over a decade ago [16]. Civitelli et al. [69]
demonstrated that when rat Cx43 promoter P1 [including 1,339 bases
5′ from the transcriptional start site (+1) and 222 bases 3′]-luciferase
transfected rat osteogenic sarcoma cells (UMR 106–01 cells) were
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increased to 2 times the basal activity. van der Heyden et al. [70] also
showed that dibutyryl-cAMP treatment enhances the activity of rat
Cx43 promoter P1 (containing exon I and 1250 bp of upstream se-
quence)-luciferase, and that enhancement of Cx43 promoter activity
by cAMP is an additional to that by the Wnt pathway, which will be
discussed below, indicating that cAMP and Wnt signaling pathways
act in parallel on the Cx43 promoter P1. However, to our knowledge,
there are no reports showing that the putative cAMP-responsive ele-
ment in the proximal Cx43 promoter is really needed for enhance-
ment of Cx43 expression by cAMP or that protein complexes bind to
the element. For example, de Montgolﬁer et al. [71] very recently
reported that in the brook trout testis, while cAMP can stimulate
the transactivation of the Cx43 promoter, it does not do this via the
C/EBP binding domain since a mutation in this sequence fails to
alter the transactivation of the Cx43 promoter.
3.1.4. Wnt pathway
Wnt genes encode a large family of secreted glycoproteins which
play important roles in directing cell fate and cell behavior, not only
during embryonic development and in adult life, but also in tumorigen-
esis [72]. Wnt proteins are thought to act via the Frizzled class of cell-
surface proteins. Receptor activation leads to inhibition of glycogen
synthase kinase 3β (GSK3β), resulting in stabilization and accumulation
of nonphosphorylated β-catenin within the cytosolic compartment. In-
creased abundance of this pool is associatedwith entry of β-catenin into
the nucleus, where members of the T cell factor/lymphocyte enhancer
binding factor (TCF/LEF) family of transcription factors physically inter-
act with β-catenin. In the nucleus, before Wnt signaling, TCF/LEF mem-
bers bind to DNA with sequence speciﬁcity in promoter and enhancer
regions of target genes, and alongwith Groucho and C-terminal binding
protein (CtBP), often repress gene expression. Nuclearly localized
β-catenin/TCF complexes are supposed to activate transcription of
target genes by binding to the speciﬁc consensus sequence A/TA/
TCAAAG, known as the TCF/LEF binding site.
van der Heyden et al. [70] performed a computer search for TCF/LEF
regulatory elements in the rat Cx43 promoter P1 and found that this
promoter contains two TCF/LEF binding consensus sequences in oppo-
site orientations, i.e., TCF/LEF site 1 is located at −1,394 bp while site
2 is located at −714 bp with respect to the transcription start site,
and a third consensus sequence is found in the ﬁrst intron following a
non-translated short exon. Two similar TCF/LEF motifs are also found
in the human and mouse Cx43 promoters partly at similar positions,
and a third one is located in the ﬁrst intron [17,73].
In fact, several studies have suggested that Cx43 acts as a functional
target of Wnt1 signaling. van der Heyden et al. [70] investigated
the effects of Wnt1 overexpression on gap-junctional communication
in the rat neural-crest-derived cell line PC12. They found that Wnt1-
expressing clones display an increased electrical and chemical coupling,
which coincides with an increased expression of Cx43 mRNA and pro-
tein, whereas other connexins, Cx26, Cx32, Cx37, Cx40, and Cx45, are
not upregulated. They also showed in transient transactivation assays
in P19 EC cells thatWnt1 and Li+, an ion that mimicsWnt signaling, in-
crease transcription from the rat Cx43 promoter containing exon I and
1250 bp of upstream sequence, potentially via TCF/LEF binding ele-
ments. Ai et al. [74] also reported that neonatal rat cardiomyocytes
respond to Li+ by accumulating the effector protein β-catenin and by
inducing Cx43 mRNA and protein markedly, and that by transfecting a
Cx43 promoter P1-reporter gene construct into cardiomyocytes, the
inductive effect of Wnt signaling is transcriptionally mediated.
Xia et al. [75] recently demonstrated that β-catenin directly
binds to the Cx43promoter, stimulatingCx43 expression and functional
gap junctions between osteocytes. They reported three ﬁndings:
(i) ﬂuid ﬂow shear stress and prostaglandin E2 (PGE2) activate
phosphoinositide-3 kinase (PI3K)/Akt signaling, which increases the
levels of Cx43 expression and gap junction activity; (ii) the independentactivation of PI3K/Akt and cAMP protein kinase A signaling by PGE2
converges through the downstream inactivation of GSK-3β and subse-
quent activation of β-catenin pathway; (iii) PGE2-induced PI3K/Akt
signaling leads to inactivation of GSK-3β followed by nuclear translo-
cation and accumulation of β-catenin, which associates with the Cx43
promoter to transcriptionally regulate Cx43 expression.
3.2. Cell type-dependent transcription factors and biological substances
that regulate connexin expression
In addition to the maintenance of basal level of connexin tran-
scription by the cell type-independent (ubiquitous) transcription fac-
tors such as Sp1 and AP-1, the tissue-speciﬁc expression of different
connexin genes depends on additional cell type-speciﬁc activators
or repressors. Although the molecular mechanisms that regulate cell
type-speciﬁc transcription of each connexin gene are still not well un-
derstood, recent studies have led to a better understanding of the
roles of some cell-type-dependent transcription factors in regulation
of connexin expression. For example, a great deal of knowledge has
been accumulated on the crucial roles of transcription factors in car-
diac development including development of the cardiac conduction
system and cardiac connexin (Cx30.2, Cx40, Cx43, Cx45) expression
in the heart [76–79].
3.2.1. Homeobox proteins
A homeobox is about 180 base pairs long and encodes a 60-aa
domain (the homeodomain) which when expressed (i.e. as protein)
can bind DNA. Homeobox-containing genes encode transcription
factors (homeobox proteins) that typically switch on/off cascades of
other genes. The homeodomain binds DNA in a sequence-speciﬁc
manner. However, the speciﬁcity of a single homeodomain protein is
usually not enough to recognize only its desired target genes. Most
of the time, homeodomain proteins act in the promoter region of
their target genes as complexes with other transcription factors.
3.2.1.1. Nkx2.5. Nkx2.5 is a homeodomain-containing transcription
factor critical for cardiac development in species ranging from Dro-
sophila to humans [80,81]. Heterozygous mutations of Nkx2.5 in
humans cause congenital heart disease [82]. Mutations that affect
DNA binding are associated with cardiac conduction defects or
heart block. Nkx2.5 mRNA and protein are transiently upregulated
during the formation of cardiac conduction system relative to the
surrounding myocardium in embryonic chick, mouse, and human
hearts, suggesting a role in the development of the conduction sys-
tem [83].
Potential Nkx2.5-binding sites have been identiﬁed in the proxi-
mal promoters P1 of mouse/rat Cx40 and rat Cx43 genes. In fact, Lin-
hares et al. [51] demonstrated that Nkx2.5 can interact speciﬁcally
with the potential binding site present in the minimal promoter re-
gion of the mouse Cx40.
From the multiple experimental results obtained for mice expres-
sing wild-type and a mutant Nkx2.5 and for Nkx2.5 homozygous or
heterozygous knockout mice, we may conclude that Nkx2.5 can act
as an activator as well as repressor of Cx43. Kasahara et al. [84a]
reported that expression of Cx40 and Cx43 was dramatically de-
creased in the transgenic heart expressing a DNA binding-impaired
mutant of mouse Nkx2.5, suggesting a positive role of Nkx2.5 in
Cx40 and Cx43 gene regulation. A subsequent study by Kasahara et
al. [84b] demonstrated that cardiomyocytes expressing wild-type
Nkx2.5 or a putative transcriptionally active mutant (carboxyl-termi-
nus deletion mutant) had dramatically reduced expression of Cx43,
and that Cx43 was downregulated in wild-type Nkx2.5 adenovirus-
infected adult cardiomyocytes as early as 16 h after infection, indicat-
ing that Cx43 downregulation is due to Nkx2.5 overexpression but
not due to heart failure phenotype in vivo. Teunissen et al. [56] also
reported that Cx43 protein and mRNA in rat primary neonatal
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tion with adenovirus encoding Nkx2.5, and that the rat Cx43 proximal
promoter P1 was down-regulated approximately twofold upon
Nkx2.5 overexpression. These results showed that Nkx2.5 can act as
an activator as well as repressor of Cx43.
Jay et al. [85] found that an entire population of Cx40 (−)/Cx45
(+) cells is missing in the atrioventricular node of Nkx2.5 heterozy-
gous knockout mice but that, surprisingly, the cellular expression of
Cx40, the major gap junction isoform of Purkinje ﬁbers and a putative
Nkx2.5 target, is unaffected. These data demonstrate that half-normal
gene dosage of Nkx2.5 is sufﬁcient for speciﬁc expression of Cx40 in
the conduction system.
Dupays et al. [86] investigated cardiac connexin expression in the
cardiovascular systems of wild-type and Nkx2.5-knockout 9.2 days
post-conception (dpc) mouse embryos and found that the disruption
of the Nkx2.5 gene in the mouse heart results in the loss of Cx43 (due
in part to the poor development of the ventricular trabecular net-
work) and downregulation of Cx45 gene expression. These results in-
dicate that Nkx2.5 is involved in the transcriptional regulation of the
Cx45 gene expression. Concerning Nkx2.5 haploinsufﬁciency, they
showed that RNA extracts from wild-type and heterozygous mutant
embryos expressed the Cx45, −43, and −40 genes, and that there
were no marked differences between wild-type and heterozygous
mutant embryos, suggesting that half-normal gene dosage of Nkx2.5
is sufﬁcient for expression of Cx45, Cx43, and Cx40 in the hearts of
9.2 dpc mouse embryos.
Pashmforoush et al. [87] generated mice with a ventricular-
restricted knockout of Nkx2.5, which display no structural defects
but have progressive complete heart block, and massive trabecular
muscle overgrowth found in some patients with Nkx2.5 mutations.
They found that Cx40 was virtually absent in the adult mutant con-
duction system, while present in the neonatal mice. These data
were consistent with Nkx2.5 being a positive regulator of Cx40 gene
expression and further suggest a speciﬁc role for Nkx2.5 in the post-
natal conduction system maturation and maintenance.
3.2.1.2. Shox2. Shox2 encodes a member of a small subfamily of paired,
related homeodomain transcription factors that has been identiﬁed by
virtue of its sequence similarity to the short-stature homeobox gene
SHOX, causing various short-stature syndromes.
Blaschke et al. [88] generated Shox2 knockout mice. Homozygous
mutant embryos were embryonic lethal at 11.5 to 13.5 dpc and exhib-
ited severe hypoplasia of the sinus venosus myocardium. They
showed aberrant expression of Cx40, Cx43, and Nkx2.5 within the
SAN region. Similarly, Espinoza-Lewis et al. [89] reported that Shox2
is restrictedly expressed in the sinus venosus region including the
SAN and the sinus valves during embryonic mouse heart develop-
ment. Shox2 null mutation resulted in embryonic lethality due to car-
diovascular defects, including bradycardia and severely hypoplastic
SAN and sinus valves. Cx40 together with Nkx2.5 and natriuretic pre-
cursor peptide A (Nppa) was ectopically activated in the mutant SAN,
where Tbx3 expression was lost. As described below, Tbx3 represses
Cx40 expression by directly binding to the promoter of Cx40 gene.
Thus, it has been suggested that Shox2 operates upstream of
Nkx2.5, Tbx3, Cx40, and Cx43 to regulate the SAN genetic program.
3.2.1.3. Homeodomain-only protein (Hop).Hop encodes a 73 amino acid
protein that contains a domain (the 60 amino acid homeodomain)
homologous to those seen in homeobox transcription factors. Unlike
all other known homeobox transcription factors, Hop does not directly
bindDNA. It is expressed in the embryonic heart and plays an important
role in development of the adult cardiac conduction system.
Ismat et al. [90] generated Hop knockout mice and found signiﬁcant
reduction in Cx40, but not Cx43, mRNA expression in hearts from
homozygous knockout mice. Although in Hop heterozygous knockout
mice, Cx40 protein is expressed throughout the cardiac conductionsystem, Cx40 expression is markedly downregulated in the region
of the AVN and proximal cardiac conduction system in homozygous
knockout mice. A subsequent study by Liu et al. [91] described that in
transgenicmice overexpressingHop, atrial Cx40 expressionwas reduced
in left ventricular hypertrophy and normalized by TSA, whereas Cx43
expression was not changed. These results indicate that adequate
amount of Hop expression is required for proper expression and local-
ization of Cx40 in the cardiac conduction system.
3.2.1.4. Iroquois homeobox gene 3 (Irx3). The Iroquois homeobox (Irx)
gene family of transcription factors contains a highly conserved DNA-
binding homeodomain of the 3-amino acid loop extension superclass
and is characterized by an 11-amino acid Iro motif. Irx genes have
evolutionarily conserved roles during embryonic development [92]
and can act as either repressors or activators of gene expression
depending on the cellular context. All six Irx genes are expressed in
partially overlapping patterns in the developing mouse heart [93,94].
Zhang et al. [95] very recently showed that Irx3 antithetically
regulates Cx43 and Cx40 in the cardiac His–Purkinje network: Irx3
directly represses Cx43 transcription and indirectly activates Cx40 tran-
scription. Promoter analysis of cardiac connexins (Cx40, Cx43, Cx45,
and Cx30.2) revealed that the Cx43 promoter contains an evolutionarily
conserved element harboring a putative Irx3 binding site, which over-
laps with an Nkx2.5 binding motif (Irx/NKE) immediately upstream of
conserved T-box binding elements. Coimmunoprecipitation analysis
showed that Irx3 can form a protein complex with Nkx2.5. They
found that Irx3 indeed antagonizes Nkx2.5-dependent activation of a
Cx43-luciferase reporter containing 1.68 kb of the endogenous promot-
er sequence in transfected COS7 cells. Furthermore, three point muta-
tions, made to alter predicted core binding sequences recognized by
Irx3, diminished the ability of Irx3 to exert repression of Cx43-luciferase
in the presence of increasing amounts of Nkx2.5. These results indicate
that in the proximal VCS, where these transcription factors at expressed
at high levels, Irx3 could therefore repress Nkx2.5-mediated activation
of Cx43 transcription.
3.2.2. T-box transcription factors (Tbx5, Tbx2, Tbx3, Tbx18)
T-box transcription factors containing the T-box, which possesses
a helix-loop-helix-type DNA-binding domain, form a large family that
plays a crucial role in several developmental processes [96–98]. The
T-box, however, is not only a conserved DNA-binding region, but
also a conserved interaction domain for other transcription factors,
chromatin remodeling complexes and histone-modifying enzymes
involved in transcriptional control [79]. In mouse and man, 17 Tbx
genes organized in ﬁve subfamilies are present. This family consti-
tutes activators (e.g., Tbx5) and repressors (e.g., Tbx2 and Tbx3) of
transcription that recognize the same binding element.
3.2.2.1. Tbx5. Tbx5 is one member of a transcription factor family
containing the T-box. Tbx5 has been implicated in vertebrate tissue
patterning and differentiation [96]. A role for Tbx5 in cardiac mor-
phogenesis has been implied from studies of Holt–Oram syndrome,
a rare autosomal dominant human disease caused by Tbx5mutations
[99–101]. Holt–Oram syndrome patients invariably exhibit upper
limb malformations and have high incidences of both congenital
heart disease, such as tetralogy of Fallot or hypoplastic left heart
syndrome [102–104], and abnormal cardiac electrophysiology
(particularly atrioventricular block). Tbx5 has a unique pattern of
expression; transcripts are abundant in the posterior regions of
the embryonic heart and predominate in the myocardium of the left
atria, right atria, left ventricle, inﬂow tract (IFT), atrioventricular canal
(AVC), inner curvature, and the atrial septum. Tbx5 is also expressed
in the central conduction system (CCS), comprising the SA node, atrio-
ventricular junction including the AV node, and the interventricular
(IV) ring including its derivatives, the retroaortic root branch, right
atrioventricular ring bundle, atrioventricular bundle (AVB), and
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sent from the right ventricle and outﬂow tract (OFT) [104–106].
Potential T-box binding sites have been identiﬁed in rat and
mouse Cx40 promoters. Bruneau et al. [107] found ﬁve potential
T-box binding sites in 1-kb fragments of mouse and rat Cx40 promoters
and showed that Tbx5 binds to at least two of those sites. Linhares et al.
[51] also demonstrated binding of Tbx5 to the putative T-box binding
site with the mouse proximal Cx40 promoter (150 bps upstream of
the transcription start site).
A crucial role of Tbx5 in regulation of Cx40 expression has been
revealed by Tbx5 heterozygous knockout (haploinsufﬁcient) mice, a
model of human Holt–Oram syndrome. Bruneau et al. [107] found
that Tbx5 haploinsufﬁciency markedly decreased Cx40 mRNA tran-
scription in the heart, indicating that Cx40 is a Tbx5 target gene and
that half-normal gene dosage of Tbx5 is insufﬁcient for expression
of Cx40. They also showed that when the mouse Cx40 promoter con-
tained within a 1010-bp fragment joined with reporter luciferase
construct was cotransfected with RSV-promoted Tbx5 cDNA into
noncardiac cells (CV-1), Cx40 promoter activity increased more
than 20-fold, demonstrating that the Cx40 promoter is a direct Tbx5
target. Furthermore, they observed synergistic activation of the
mouse Cx40 promoter by Tbx5 and Nkx2.5.
In contrast to Nkx2.5, overexpression of Tbx5 has not been
reported to downregulate connexin expression. Using clones of the
P19Cl6 embryonal carcinoma cell line stably transfected with Tbx5,
Fijnvandraat et al. [108a] found a strong positive correlation between
the levels of Tbx5 transgenemRNA and of Cx40mRNA, indicating that
Tbx5 does not function as a repressor of connexin expression.
Development of ventricular conduction system including Cx40
expression requires cooperation between Tbx5 and Nkx2.5. Moskowitz
et al. [108b] found that Cx40 expression is absent from the region of the
AV bundle and bundle branches of Tbx5+/−/Nkx2.5+/−mice, and these
compound heterozygous mice exhibit ventricular conduction system
delays.
3.2.2.2. Tbx2 and Tbx3. Among the T-box transcription factors, Tbx2
and Tbx3 function as repressors of transcription, including that of
Cx40 and Cx43 expression. Christoffels et al. [109] showed that
when the putative regulatory sequences of mouse Cx40 (a 1.2-kb
mouse Cx40 upstream region from −1,196 to +62 relative to the
transcription start site) and rat Cx43 (a 1.6-kb rat Cx43 upstream re-
gion from −1,338 to +281) were coupled to the luciferase reporter
gene and transfected to Cos-7 or HEK cells, Cx40 promoter activity
and to a lesser extent Cx43 promoter activity were repressed by
Tbx2. They also found that at mouse developmental stages (embryon-
ic days 9.5–14.5), expression patterns of Tbx2 and cardiac chamber-
speciﬁc genes including Cx40 and Cx43 were mutually exclusive in
the myocardium. Tbx2 is expressed in the IFT, AVC, inner curvature,
and OFT, whereas no Tbx2 expression could be observed in the atrial
and ventricular chamber myocardium. On the other hand, Cx40 and
Cx43 are expressed in the atrial and ventricular chamber myocardi-
um, but absent in the IFT, AVC, inner curvature, and OFT. These data
indicate a role of Tbx2 in the repression of the connexin genes in
hearts in vivo.
Hoogaars et al. [106] showed that, similarly to Tbx2, the patterns
of Tbx3 and cardiac chamber-speciﬁc genes including Cx40 and
Cx43 are mutually exclusive throughout all stages of mouse heart de-
velopment (E9-E17.5). In the formed heart, Tbx3 is expressed in the
central conduction system, comprising the SAN, AVN, bundle and
proximal BBs, as well as the internodal regions and the atrioventricu-
lar region. Expression of Cx40 and Cx43 is speciﬁcally absent from the
Tbx3 expression domain. However, there are some exceptions: at
E15.5, weak Tbx3 expression protrudes further into the proximal BB
which by then also expresses Cx40, and at E17.5, when the heart
has reached its mature form, the AVB expresses low levels of Cx40,
coexpressed with Tbx3. Hoogaars et al. [106] also demonstrated thatTbx3 dose-dependently represses the activity of mouse Cx40 promoter
contained in 1.2-kbp Cx40 upstream regulatory region−1196 to+62
relative to the transcription start site. A subsequent study using ectopic
expression of Tbx3 in mice done by Hoogaars et al. [110] revealed that
Tbx3 represses the atrial phenotype including Cx43 and Cx40 expres-
sion and imposes the SAN phenotype including Cx30.2 expression on
the atria. The mice displayed arrhythmias and developed functional ec-
topic pacemakers. Chromatin immunoprecipitation showed that Tbx3
speciﬁcally interacts with the TBE-containing DNA region of the Cx43
promoter, indicating that Tbx3directly represses Cx43. These data iden-
tify a Tbx3-dependent pathway for the speciﬁcation and formation of
the SAN, and show that Tbx3 regulates the pacemaker gene expression
program and phenotype.
Concerning molecular mechanisms by which Tbx2 and Tbx3 re-
press Cx43 expression, Boogerd et al. [111] demonstrated that muscle
segment homeobox genes Msx1 and Msx2 together with Tbx2 and
Tbx3 suppress Cx43 promoter activity and down regulate Cx43 gene
activity in a rat heart-derived cell line. Using chromatin immunopre-
cipitation analysis they demonstrated that Msx1 can bind the Cx43
promoter at a conserved binding site located in close proximity to a
previously deﬁned T-box binding site, and that the activity of Msx
proteins on this promoter appears dependent in the presence of
Tbx3. These data indicate that Msx1 and Msx2 can function in concert
with the T-box proteins to suppress Cx43 and other working myocar-
dial genes.
It should be noted that expression of Cx45 in the heart seems to be
regulated independently of repressive function of Tbx2 and Tbx3, be-
cause in the adult myocardium, Cx45 is expressed in all components
of the conduction system including the Tbx3-positive central conduc-
tion system and the Tbx3-negative peripheral conduction system
encompassing the distal part of the BBs plus the peripheral ventricu-
lar conduction network (the Purkinje ﬁbers).
Apart from regulation of connexin expression in the heart, Chen
et al. [112] reported that in osteoblast-like cells, the mouse Cx43 pro-
moter (−479 to 0) contains two Tbx2 binding sites. This binding was
dependent on the TCACAC consensus sequence, and transient trans-
fection analysis with a Cx43 promoter-driven lacZ reporter construct
revealed negative regulation of Cx43 transcription mediated by these
two Tbx2 binding sites.
3.2.2.3. Tbx18. It has been shown that Tbx18-expressing mesenchymal
precursor cells give rise to the SAN, especially the head region, which
represents ~75% of the SAN volume and originates pacemaker activity
in the early embryonic heart [113]. In contrast, the surrounding right
atrium is negative for Tbx18 and originates from Isl1-expressing sec-
ond heart ﬁeld mesodermal progenitors [114].
Kapoor et al. [115] recently demonstrated that Tbx18 speciﬁcally
down-regulates Cx43 at both the mRNA and protein levels, while
having no effect on Cx40 or Cx45. Additionally, Cx43 promoter activ-
ity is directly repressed by Tbx18 and Tbx3, but not by Tbx20, which
plays a role during ventricular chamber formation.
3.2.3. GATA family
GATA transcription factors contain a highly conserved DNA bind-
ing domain consisting of two zinc ﬁngers of the motif Cys-X2-Cys-
X17-Cys-X2-Cys that directs binding to the nucleotide sequence ele-
ment (A/T)GATA(A/G) [116]. Based on their expression patterns, the
GATA proteins have been divided into two subfamilies, GATA-1, -2,
and -3 and GATA-4, -5, and -6. GATA-1, -2, and -3 genes are promi-
nently expressed in hematopoietic stem cells, where they regulate
differentiation-speciﬁc gene expression in T-lymphocytes, erythroid
cells, and megakaryocytes. GATA-4, -5, and -6 genes are expressed
in various mesoderm- and endoderm-derived tissues such as heart,
liver, lung, gonad, and gut, where they play critical roles in regulating
tissue-speciﬁc gene expression.
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with its putative site (−49, –36) in the rat/mouse Cx40 proximal pro-
moter, and that the coexpression of GATA4 induced an approximate
six-fold increase in luciferase activity from −1190/+121Cx40Luc.
Addition of Nkx2.5 with GATA4 led to a 10-fold increase in activation.
The same effect was observed when the minimal promoter−50/+121
Cx40Luc construct was used, indicating that this region contains the
sites required for activation of Cx40 expression by both Nkx2.5 and
GATA4 transcription factors.
Munshi et al. [2] performed Cx30.2 (Gjd3) enhancer analysis and
identiﬁed GATA4 as a regulator of atrioventricular delay via regula-
tion of Cx30.2 expression. They found that A 660 bp Cx30.2 enhancer
is sufﬁcient to direct atrioventricular conduction system-speciﬁc gene
expression, the Cx30.2 minimal enhancer harbors one GATA element
and two T-box elements that direct DNA binding and ternary complex
formation of Gata4 and Tbx5.
Fig. 1 summarizes a current view of regulation of cardiac connexin
expression in relation to myocardial cell lineages.
3.2.4. HNF-1
HNF-1 is a transcription factor whose expression has been posi-
tively correlated with the differentiated hepatic phenotype and posi-
tively regulates many liver-speciﬁc genes, e.g., α1-antitrypsin,
albumin, and α- and β-ﬁbrinogen [117]. Two isoforms, HNF-1α andFig. 1. A current view of regulation of cardiac connexin expression in relation to myocardial ce
node; BB, bundle branch; LV, left ventricle; RV, right ventricle; SAN, sinoatrial node; VCS, ventHNF-1β, are known; the former is highly expressed in adult liver,
whereas the latter is expressed earlier in development. HNF-1 iso-
mers dimerize in a homomeric or heteromeric manner before binding
to DNA, and each combination can have distinct effects on transcrip-
tional control, depending upon the target gene. HNF-1 is also
expressed in other tissues such as kidney, gut, and pancreas, where
it controls the expression of many genes.
Hennemann et al. [34] ﬁrst reported that the promoter region of
the mouse Cx32 gene contains two putative binding sites for HNF-1
within 680 bp upstream of the main transcription start site. Piechocki
et al. [31] showed that promoter activity of the rat Cx32 promoter (nt
−753 to −33) linked to the luciferase gene was correlated with the
binding of HNF-1 to two HNF-1 consensus sites centered at −187
and −736, and that expression of HNF-1 and binding to these ele-
ments were only observed with rat hepatoma (MH1C1) cells that ex-
press endogenous Cx32. Kofﬂer et al. [35] demonstrated that stable
transfection of non-Cx32-expressing WB-F344 rat liver epithelial
cells with HNF-1α stimulated a transfected Cx32 promoter element
(mp−244 to−33), binding of HNF-1α to the−187 site, and expres-
sion of endogenous Cx32, and that Cx32 expression was also signiﬁ-
cantly decreased in HNF-1α (−/−) mice. These data suggest that
HNF-1 determines the cell-speciﬁc expression of Cx32 based on the
cell-type-independent activation of Cx32 promoter by ubiquitous
transcription factors such as Sp1 as described above.ll lineages. AVB, atrioventricular bundle; AVC, atrioventricular canal; AVN, atrioventricular
ricular conduction system.
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Mist1 is one of the members of the basic helix-loop-helix (bHLH)
protein family that are instrumental the in development of numerous
organ systems. Rukstalis et al. [118] found that Mist1 knockout (KO)
pancreatic acini are deﬁcient in gap-junctional intercellular commu-
nication, mainly due to the loss of Cx32 expression, and that Cx32
mRNA and protein levels are greatly reduced in the Mist1 KO exocrine
pancreas, whereas Mist1 KO acinar cells continue to express the Cx26
gene. They also showed that co-transfection of cells with the mouse
Cx32 P1 promoter (−680 to +20) -luciferase reporter plasmid
(Cx32p-Luc) and an expression plasmid encoding Mist1 generated a
15- to 20-fold increase in Cx32p-Luc expression, whereas no other
bHLH transcription factor such as E12, E47, HEB, PTF1-p48, NeuroD,
MyoD, and Mash1, could activate expression of the Cx32p-Luc gene.
The ability of Mist1 to activate expression of the Cx32p-Luc gene
was dependent on its DNA binding and dimerization properties.
From those results, it is concluded that an active Mist1 protein is re-
quired to generate full Cx32 gene expression in secretory acinar cells.
Concerning tissue-speciﬁc Cx32 expression, combined data on
Mist1 [118] and HNF-1 indicate that there are at least two different
activation mechanisms of Cx32 expression in the epithelial cell:
Mist1-dependent expression in secretory exocrine cells, including
the pancreas, submandibular gland, parotid gland and seminal vesi-
cles and HNF-1-dependent expression in the hepatocyte. Rukstalis
et al. [118] described that Cx32 and Mist1 co-expression is observed
in all secretory exocrine cells, including the pancreas, submandibular
gland, parotid gland and seminal vesicles, whereas hepatocytes ex-
press Cx32 but not Mist1. Furthermore, they showed that in the
liver tissue of Mist1 KO mice, expression of Cx32 transcripts and for-
mation of Cx32-containing gap junction plaques remained
unchanged, indicating that Cx32 expression in the liver is indepen-
dent of Mist1. On the other hand, Kofﬂer et al. [35] reported that
Cx32 mRNA content in HNF-1α homozygous KO mouse liver was ap-
proximately one-third that of HNF-1a heterozygous KO mice, sug-
gesting a crucial effect of HNF-1 on Cx32 in the hepatocyte.
3.2.6. Sox10 and early growth response gene-2 (Egr2/Knox20)
The Sox proteins belong to the high mobility group (HMG) box su-
perfamily of DNA-binding proteins. Among them, Sox10 is ﬁrst
expressed widely in cells of the neural crest at the time of their emer-
gence, and later in neural crest cells that contribute to the melanocyte
lineage and to the forming peripheral nervous system. Its expression
is detected in the enteric, sensory, and sympathetic ganglia as well as
along nerves in a manner typical for the Schwann cell lineage [119].
The early growth response gene-2 (Egr2/Knox20) gene was origi-
nally identiﬁed as a serum response immediate-early gene that en-
codes a protein with three tandem zinc ﬁngers of cys(2)-his(2)
class [120–122]. Egr2/Krox20 knockout mice showed disrupted hind-
brain segmentation and development and a block of Schwann cells at
an early stage of differentiation [123,124].
Mutations in Sox10 genes are discovered in patients with various
hereditary neurological diseases includingWaardenburg–Hirschsprung
disease or Shah-Waardenburg syndrome (WS4), andWS4with periph-
eral neuropathy consistent with Charcot–Marie–Tooth disease type I
[119]. Mutations in Egr2/Krox20 gene are identiﬁed in patients with
congenital hypomyelinating neuropathy and a family with Charcot–
Marie–Tooth disease type 1D (CMT1) [124].
Bondurand et al. [36] showed that Sox10, in synergy with Egr2/
Knox20, strongly activates expression of Cx32, a major protein of
peripheral myelin, in vitro by directly binding to its nerve-speciﬁc pro-
moter P2, and that Sox10 and Egr2 mutants identiﬁed in patients with
peripheral myelin defects failed to transactivate the Cx32 promoter P2.
They also demonstrated that a T-to-G point mutation at position
−528 of the Cx32 promoter P2 identiﬁed in some CMTX1 patients elim-
inates binding and activation by Sox10. Similarly, Houlden et al. [37]
identiﬁed a large family with Charcot–Marie–Tooth disease with aG-to-C point mutation at position −526 bp of the Cx32 promoter P2
and showed that this mutation reduced the activity of the Cx32 pro-
moter and the afﬁnity for Sox10 binding. These data suggest that in-
teraction between the Cx32 P2 promoter, Sox10, and Egr2 plays an
important role in Cx32 expression in the Schwann cell.
In addition to Cx32, Jungbluth et al. [125] reported that segment-
speciﬁc expression of Cx31 in the mouse embryonic hindbrain is pos-
itively regulated by Egr-2/Krox20. They found that the spatiotempo-
ral patterns of Cx31 expression in rhombomeres 3 and 5 and in the
boundary cap cells are very similar to the expression pattern of
Egr2/Krox20, and that in Egr2/Krox20 KO embryos, no Cx31 expres-
sion was detectable in the developing hindbrain, whereas expression
of Cx31 in other sites nonoverlapping with that of Egr2/Krox20, such
as in the posterior end of the embryonic body axis, was not affected in
Egr2/Krox20 KO embryos.
Furthermore, Schlierf et al. [126] showed that Sox10 regulates
not only Cx32 expression but also Cx47 (Gjc2) expression in oligo-
dendrocytes. Osaka et al. [127] identiﬁed a homozygous mutation
(c.-167A>G) within the Cx47 (GJC2) promoter at a potent SOX10
binding site in a patient with mild Pelizaeus–Merzbacher-like disease
(PMLD). Functionally, this mutation completely abolishes the SOX10
binding and attenuated mouse Cx47 promoter activity in human glio-
blastoma U138 cells. Combes et al. also found this mutation in 7 PMLD
patients. However, their functional analysis of the c.-167A>Gmutation
on the human Cx47 promoter showed a higher activity with mutated
promoter than with the wild type in COS-7 and HEK293 cells. Thus,
the functional consequences of this mutation remain to be fully
elucidated.
3.2.7. Estrogen and progesterone
Cx43 expressed in the uterus is thought to play a critical role in the
onset of labor by allowing for an increase in myometrial cell coupling
and coordinated synchronous contraction of the muscle at the end of
pregnancy. Before the onset of labor, there is a dramatic increase in
both mRNA and protein levels of Cx43 in the myometrium
[128,129]. The Cx43 gene in the myometrium is under the control of
steroid hormones, being up-regulated by estrogen and down-
regulated by progesterone (PR) [130]. Yu et al. [16] showed that the
rat Cx43 promoter contains several sequences resembling half the
palindromic estrogen response elements (half-EREs); depending on
the concentration of estrogen, the half-EREs were functional when
cotransfected with estrogen receptor cDNA into HeLa cells.
However, Oltra et al. [131] described that these half-EREs are not re-
quired for the induction of the Cx43 gene; a promoter containing only
145 nucleotides and lacking all half-EREs was shown to be sufﬁcient
to achieve full estrogen response. It has also been reported that elevated
Cx43 expression in term human myometrium is independent of myo-
metrial estrogen receptors [58]. On the other hand, it has been shown
that the expression of several AP-1 family transcription factors (c-jun
and c-fos family of transcription activators) is dramatically increased
in the myometrium before the onset of labor and that this expression
is regulated by both mechanical and hormonal stimuli [17,58,64].
Therefore, AP-1 proteins play crucial roles in positive regulation of
Cx43 expression in the pregnant myometrium as described above.
PG signaling plays important roles in the maintenance of pregnancy
by repressing the expression of labor-associated proteins including
Cx43. Dong et al. [132] showed that PR represses transcription of Cx43
gene, an effect dependent on the presence of AP-1 site within the prox-
imal Cx43 promoter. p54nrb (non-POU-domain-containing, octamer
binding protein), can function as a PR corepressor and interacts directly
with PR independent of progesterone. Mutation of AP-1 site abolishes
PR-mediated repression and decreases the recruitment of PR and
p54nrb onto the Gja1 promoter. Furthermore, knockdown p54nrb ex-
pression by small interfering RNA alleviates PR-mediated repression
on Cx43 transcription, whereas overexpression of p54nrb enhances it.
In the physiological context of pregnancy, p54nrb protein levels
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indicate that decreased expression of p54nrb at the time of labor may
act to derepress PR-mediated inhibition on Cx43 expression and con-
tribute to the initiation of labor.
Besides AP-1 proteins, Oltra et al. [131] reported that Ini, a small
nuclear zinc-ﬁnger protein, actively participates in the positive re-
sponse of Cx43 expression to estrogen. They showed that Ini binds
to the rat proximal Cx43 promoter between −71 and −34, its ex-
pression is ubiquitous, and in the uterus is upregulated by estrogen.
Furthermore, transient transfection experiments performed with es-
trogen receptor alpha cDNA show that overexpression of Ini en-
hances, in a dose-dependent fashion, the up-regulation of the Cx43
gene by estrogen.
3.2.8. Thyroid hormone and parathyroid hormone
Stock and Sies [133] demonstrated that after treatment with
thyroid hormone Cx43 mRNAwas elevated 2.1-fold in rat liver samples
as compared to controls, while there was no change in the heart. They
identiﬁed thyroid hormone response elements in the rat Cx43 promoter
region at position−480 to−464 and showed that the Cx-480 element
formed stronger complexes with thyroid hormone receptor alpha/
retinoid X receptor alpha heterodimers than with vitamin D receptor/
retinoid X receptor alpha heterodimers. In transfected Cos-7 cells, pro-
moter activation via this element was observed after treatment with
3,3′,5-triiodo-L-thyronine. de Montgolﬁer et al. [71] reported that
Cx43 is expressed in the Sertoli cells of rainbow trout and that triiodo-
thyronine (T3) regulates testicular Cx43 expression in brook trout
testis. Single thyroid hormone (tr-beta) (−112 to −107) response
elements are identiﬁed and electrophoretic mobility shift assays indi-
cate the presence of competitive protein binding sites. Sequential de-
letion and point mutations in the tr-beta response element indicate
that T3 stimulates Cx43 expression via direct regulation of gene
transcription.
Mitchell et al. [134] showed that in the rat osteosarcoma cell line,
parathyroid hormone (PTH) induced a 4-fold increase in activity of
Cx43 promoter containing 1.6 kb 5′ of the transcription start site, in
which responsive sequence was localized to between −31 and
+1 bp. They demonstrated that PTH treatment of transgenic mice
containing the 1.6 kb promoter luciferase construct induced increases
in luciferase and Cx43 immunoreactivity in bone cells underlying the
tibial growth plate. They also found that the full Cx43 3′UTR conferred
a 3-fold response to PTH when placed 3′ of a CMV-luciferase con-
struct, in which responsive sequence was localized to between 2510
and 3132 of the 3′-UTR. These data indicate that PTH responsive se-
quences are present in the Cx43 promoter and 3′-UTR, suggesting
that transcriptional and posttranscriptional pathways operate to reg-
ulate PTH-induced Cx43 expression in osteoblast cells.
3.2.9. Other transcription regulators of connexin expression
Martin et al. [135] reported that the transcriptional repressor
neuron-restrictive silencer factor (NRSF) controls neuron- and beta-
cell-speciﬁc expression of Cx36 expression. They identiﬁed a putative
neuron-restrictive silencer element conserved between rodent and
human species in a 2043-bp fragment of the human Cx36 promoter,
and showed that NRSF binds the neuron-restrictive silencer element.
They also demonstrated that this factor is not expressed in insulin-
secreting cells and neurons; viral gene transfer of NRSF in insulin-
secreting beta-cell lines induced a marked reduction in Cx36 mRNA;
repression of Cx36 expression by NRSF is mediated through the re-
cruitment of histone deacetylase to the promoter of neuronal genes.
Ciliary neurotrophic factor (CNTF) is a member of the IL-6 family
that is produced as a nonsecreted cytosolic cytokine by astrocytes
within the central nervous system and has its speciﬁc receptor,
termed ciliary neurotrophic factor receptor alpha (CNTFRalpha),
located on neuronal cell membranes. Ozog et al. [136] demonstrated
that the heterodimer CNTF–CNTFRalpha signiﬁcantly increased Cx43mRNA in normal astrocytes in a Janus tyrosine kinase/signal transducer
and activator of transcription (JAK/STAT)-dependent manner, whereas
CNTF–CNTFRalpha did not alter Cx30 mRNA levels. In the promoter P1
region of mouse Cx43, they identiﬁed three putative CNTF-response
elements (binding sites for STAT3 dimers that contain base sequences
TTCCN3-5AA) and showed that these three elements, located at regions
−1510,−1179, and−893, are essential for Cx43-regulated expression
by CNTF–CNTFRalpha.
4. Epigenetic regulation of connexin expression
In recent years, it has become clear that epigenetic processes, such
as histone modiﬁcations, DNA methylation, and microRNA species,
are also essentially involved in connexin gene regulation [8].
4.1. Histone modiﬁcation
The involvement of histone modiﬁcations, and histone acetylation
in particular, in the control of connexin expression has been demon-
strated by works with histone deacetylase inhibitor (HDACi) [8]. Very
few studies have actually addressed the molecular mechanisms that
underlie the effects of HDACi on connexin expression.
Ogawa et al. [137] demonstrated that treatment of nonmalignant
human peritoneal mesothelial cells with a HDACi, suberoylanilide
hydroxamic acid (SAHA), at nanomolar concentrations caused a
dose-dependent increase of Cx43 mRNA and protein expression, ac-
companied with the accumulation of acetylated histones H3 and H4
in the chromatin fragments associated with Cx43 gene. From these
results, they discussed that SAHA-induced Cx43 gene expression
could be ascribed to histone H3/H4 acetylation.
Hernandez et al. [60] found that the TSA-mediated induction of
Cx43 in human prostate cancer cells depends on the recruitment of
p300/CREB-binding protein, a transcriptional coactivator displaying
histone acetyltransferase (HAT) activity, and the transcription factors
AP-1 and Sp1 to the Cx43 gene promoter. This was accompanied by
hyperacetylation of histones H4 surrounding the AP-1- and Sp1-
responsive gene elements.
Hohl and Thiel [138] reported that Cx36 gene expression was
enhanced by TSA 3.5–4x in pancreatic α (αTC1-9) and β (βTC3) cells,
but TSA was unable to trigger Cx36 transcription in neuronal SN56 or
pituitary AtT20 cells, indicating that cell type (pancreas)-speciﬁc deter-
minants are important for TSA to have an impact of the transcription of
the Cx36 gene. They found that this cell type-speciﬁc enhancement
coincident with the state of epigenetic markers for active or silenced
genes: methylation of lysine residue 9 (Lys9) of histone H3 functions
as an epigenetic marker for silenced genes, whereas methylation of
lysine residue 4 (Lys4) of histone H3 does as that for actively tran-
scribed genes. Chromatin immunoprecipitation experiments using anti-
bodies directed against methylated histone H3Lys4 or H3Lys9 showed
that Cx36 gene is activated in βTC3 cell but silenced in AtT20 cells.
Zupkovitz et al. [139] found that in mouse embryonic stem cells,
expression levels of Cx43 mRNA are reduced not only upon the loss
of HDAC1 but also in a dose-dependent manner by TSA. Chromatin
immunoprecipitation experiments demonstrated that HDAC1 is pre-
sent at the Cx43 promoter in wild-type cells, while HDAC2 is
recruited mainly in HDAC1-null cells. Analysis of chromatin modiﬁca-
tions at the Cx43 promoter revealed that the acetylations of histone
H4 and Lys9 at histone H3 are slightly reduced in the absence of
HDAC1, while the trimethylation of Lys9 at histone H3 is increased
in HDAC1-null cells. Thus, the reduced expression of Cx43 correlates
with the increased presence of the epigenetic marker for silenced
genes.
It also should be noted that HDACi's hyperacetylate nonhistones
such as cytosolic proteins, including transcription factors themselves.
Therefore, it remains to be clariﬁed whether reported effects of HDA-
Ci's on connexin expression really result from histone modiﬁcation. In
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heart, a prolonged treatment (2–3 mo) with HDACi SAHA prevents
ventricular arrhythmias, reverses conduction defects, and recovers
to a normal Cx43 distribution at intercalated disks from abnormal
presence of lateralized Cx43 on mdx cardiomyocytes without signiﬁ-
cant changes in Cx43 protein expression. Subsequently, a work by
Colussi et al. [141] provided evidence that, in mdx as well as normal
hearts, Cx43 distribution in and out of intercalated disks and its func-
tion may be regulated by the degree of Nε-lysine acetylation. They
found that global histone acetylase activity is abnormally elevated,
the acetylase P300/CBP-associated factor (PCAF) coimmunoprecipi-
tates with Cx43, which is Nε-lysine acetylated and lateralized in
mdx heart, and that the level of acetylated Cx43 is signiﬁcantly higher
in mdx than in normal control hearts. In vivo treatment of mdx with
the pan-histone acetylase inhibitor anacardic acid signiﬁcantly re-
duced Cx43 Nε-lysine acetylation and restored its association to inter-
calated disks. On the contrary, a short-term treatment (96 h) of
normal mice with SAHA, which increased total protein acetylation,
determined dissociation of Cx43 from intercalated disks and laterali-
zation. Thus, evidence is now accumulating about epigenetic process-
es meant for nonhistone protein modiﬁcation including connexins.
4.2. Gene silencing by DNA methylation of the connexin promoters
The downregulation of connexin expression is often observed in
tumors and transformed cell lines and is believed to contribute to
the loss of proliferating control. Despite intensive studies, neither de-
letion nor mutation of connexin gene has been found common in
human tumors. On the contrary, multiple studies have shown that
epigenetic inactivation through hypermethylation of the promoter
region could lead to silencing of connexin expression in various
kinds of malignant cells, and that effects of DNAmethyltransferase in-
hibitors on connexin expression depend on types of cells and connex-
ins, as summarized in a review by Vinken et al. [8]. Among them,
Chen et al. [142] reported that in human non-small cell lung cancers,
lack of Cx43 mRNA expression in adjacent normal lung tissue was sig-
niﬁcantly correlated with micrometastasis into lymph nodes and that
a higher frequency of promoter methylation was observed in Cx43
mRNA-negative patients compared with Cx43 mRNA-positive pa-
tients. Their data also indicate that promoter methylation may inter-
fere with AP-1 binding to the promoter, resulting in lack of Cx43 gene
expression. Sirnes et al. [143] very recently published a study of con-
nexin expression and promoter methylation of connexin family
members in normal colon, colorectal carcinomas, and colon cancer
cell lines. They detected expression of six [Cx43 (GJA1), Cx59
(GJA9), Cx32 (GJB1), Cx26 (GJB2), Cx45 (GJC1), Cx31.9 (GJD3)] con-
nexin genes in normal colonic tissue samples. Cx45 expression was
reduced in colorectal carcinomas and cancer cell lines compared to
normal tissue samples. A statistically signiﬁcant association is found
between the presence of promoter hypermethylation and reduced
GJC1 expression. Cx45 was restored in cell lines treated with the
demethylating drug 5-aza-2′deoxycytidine. Concerning other
connexin genes than GJC1, the authors found that in colon cancer
cell lines, the methylation status is not associated with gene
expression.
4.3. MicroRNAs
Mature microRNAs (miRNAs) are ~22-nucleotide single-stranded
non-protein-coding RNAs that inhibit the expression of speciﬁc
mRNA targets through Watson–Crick base pairing between the
miRNA ‘seed region’ and sequences commonly located in the 3
untranslated regions (UTRs). The human genome is estimated to en-
code up to 1000 miRNAs, which are either transcribed as standalone
transcripts, frequently encoding several miRNAs, or generated by
the processing of introns of protein-coding genes. The potentialroles of miRNAs in controlling connexin expression have recently
been investigated [8,144,145].
Kim et al. [146] demonstrated that the muscle-speciﬁc miRNAs,
miR-206, miR-1 and miR-133, are induced during in vitro differentia-
tion of C2C12 myoblast cells into multinucleate myotubes. Cx43 is
shown to be a direct negative target for miR-206 by luciferase report-
er assay. Anderson et al. [147] also showed that two related miRNAs,
miR-206 and miR-1, inhibit the expression of Cx43 protein during
myoblast differentiation in vitro and in vivo without altering Cx43
mRNA levels, and that Cx43 mRNA contains two binding sites for
miR-206/miR-1 in its 3′-untranslated region, both of which are re-
quired for efﬁcient downregulation
Yang et al. [148] showed that muscle-speciﬁc miRNA miR-1 is
overexpressed in individuals with coronary artery disease, and that
when overexpressed in normal or infarcted rat hearts, it exacerbates
arrhythmogenesis. Elimination of miR-1 by an antisense inhibitor in
infarcted rat hearts relieved arrhythmogenesis. miR-1 overexpression
slowed conduction by post-transcriptionally repressing Cx43. The au-
thors found that 3′-UTRs of Cx43 gene contain stretches of eight nu-
cleotides that are complementary to the ﬁrst eight nucleotides from
the 5′ end of miR-1, and proved that miR-1 binds to these nucleotides.
miR-1 is shown to reduce Cx43 levels also in isolated neonatal rat
ventricular myocytes in culture. They discussed that miR-1 may
have important pathophysiological functions in the heart, and that
is a potential antiarrhythmic target.
Callis et al. [149] showed that miR-208a is required for proper ex-
pression of Cx40. Cx40 transcript and protein levels are markedly de-
creased in Mir208a −/− hearts compared with wild-type, whereas
Cx40 transcript levels are not affected in miR-208a transgenic hearts.
No readily apparent changes in Cx43 transcript levels are detected in
either miR-208a Tg or Mir208a−/− hearts. These observations indi-
cate that Cx40 is not directly regulated by miR-208a, but instead
miR-208a targets a transcription factor associated with Cx40 and/or
required for Cx40 expression. Furthermore, they found that the 3′
UTR of Gata4 mRNA contained a predicted miR-208a target site, that
cotransfection of miR-208a with the luc-GATA4 reporter repressed
luciferase activity, and that GATA4 protein levels were elevated in
Mir208a−/− hearts compared with hearts from wild-type litter-
mates. Consistent with posttranscriptional regulation, the GATA4
transcript levels are unchanged in Mir208a−/− hearts. Taken togeth-
er, these observations demonstrate that miR-208a directly targets the
cardiac transcription factor GATA4, suggesting that miR-208a regu-
lates Cx40 expression possibly via GATA4. In addition to roles of
miR-208a on Cx40 expression, Callis et al. [149] reported several
novel ﬁndings: (a) miR-208a and miR-208b are members of miR-
208 family, are encoded within introns of αMHC and βMHC, respec-
tively, and are differentially expressed during heart development
and heart pathology, paralleling the expression of their respective
host genes, αMHC and βMHC. (b) Cardiac overexpression of miR-
208a is sufﬁcient to induce hypertrophy, which resulted in pro-
nounced repression of the miR-208 regulatory targets thyroid
hormone-associated protein 1 and myostatin, 2 negative regulators
of muscle growth and hypertrophy. (c) miR-208a is necessary for
normal cardiac conduction. miR-208a gain- and loss-of-function are
associated with arrhythmias.
Inose et al. [150] revealed Cx43, a major gap junction protein in
osteoblasts, as a target of miR-206 during osteoblast differentiation
in vivo. They ﬁrst showed that miR-206, previously viewed as a
muscle-speciﬁc miRNA, is expressed in osteoblasts, its expression de-
creases over the course of osteoblast differentiation, and that overex-
pression of miR-206 in osteoblasts inhibits their differentiation, and
conversely, knockdown of miR-206 expression promotes osteoblast
differentiation. Next, they found two putative target sequences for
miR-206 in the 3 UTR region of Cx43 and proved that ectopically
expressed miR-206 binds these sites. Furthermore, they showed
that ectopic expression of miR-206 downregulates endogenous
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Fig. 2. Regulation of connexin expression by transcriptional factors and epigenetic mechanisms including histone modiﬁcation, DNA methylation, and microRNAs. Ac, acetyl group;
CH3, methyl group; HAT, histone acetyltransferase; HDAC; histone deacetylase; miRNA, microRNA; pre-miRNA, precursor microRNA; TF, transcription factor.
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and that continuous expression of miR-206 in osteoblasts decreases
osteoblast differentiation and Cx43 protein expression. However,
when they co-expressed Cx43 together with miR-206, the inhibitory
effect of miR-206 on osteoblast differentiation is markedly rescued,
indicating that restoration of Cx43 protein expression is sufﬁcient to
obtain normal osteoblast differentiation in miR-206-expressing
osteoblasts.5. Conclusion
Here, we have reviewed regulation of connexin expression by di-
viding into gene structure of connexins, transcriptional factors, and
epigenetic regulation including histone modiﬁcation, DNA methyla-
tion, and microRNAs (Fig. 2). As detailed above, it has become clear
that in various biological processes, connexin transcription network
is modulated by a combination of multiple transcription factors, his-
tone modiﬁcations, and microRNAs. However, how the interaction
between these regulatory mechanisms takes place is still an open
question. Recently, Schlesinger et al. [151] demonstrated the validity
of a system biology approach for the study of the cardiac transcription
network, by integrating mRNA proﬁles with DNA-binding events of
key cardiac transcription factors, activating histone modiﬁcations,
and microRNA proﬁles obtained in wild-type and RNAi-mediated
knockdown. Such an approach for the study of connexins may help
us to further understand regulation of connexin gene expression
under physiological and pathological circumstances and to develop
potential connexin therapies for human diseases including cancer,
heart, and neurological disorders.Acknowledgements
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